Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

Moderna, Inc.'s share price has weakened due to declining COVID-19 vaccine demand, but its diverse asset portfolio supports future growth and returns. The company is focusing on respiratory ...

18 analysts have expressed a variety of opinions on Moderna MRNA over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

Cost of sales dropped 77% thanks to well-managed costs and strategic pivots. Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related ...

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have lost significantly in the past couple of years due to declining sales amid low demand ...

In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and ...

The Tostada is the most dated item. It was one of the six items released at Taco Bell’s first walkup location in California, per a press release, and tops a tostada shell with refried beans ...

LAKE CHARLES, La. (KPLC) - La. 14 is one of the most traveled roads in Southwest Louisiana and it will soon see new improvements. However, those improvements will lead to lane closures through next ...

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157). V940 is an investigational ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The company’s Q3 SpikeVax revenue beat estimates and guidance was ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter. He will remain chief executive officer of the biotech company.